# Project 2: Identification of combination therapy for KRAS-driven lung cancers.

> **NIH NIH P01** · DANA-FARBER CANCER INST · 2021 · $288,552

## Abstract

KRAS is a key regulatory component in a signaling pathway that involves upstream tyrosine
kinase receptors (RTK), including EGFR, and downstream effector pathways regulated by RAF,
phosphatidylinositol 3-kinase (PI3K) and Ral-GDS. Activating mutations of the KRAS proto-
oncogene are present in ~30% of lung adenocarcinomas and are among the most common
oncogenic mutations in human cancers. Although small molecule inhibitors of EGFR and other
RTKs show clinical benefit in subsets of lung cancer patients, tumors that harbor KRAS
mutations have proven refractory to both targeted and chemotherapeutic approaches, and
despite intensive efforts, no effective therapies exist for KRAS mutated lung cancers. Thus,
identifying therapeutic strategies to target lung and other human cancers that harbor KRAS
mutations remains an important unsolved problem and an area of substantial clinical need.
 In the previous funding period, we investigated the non-canonical IB kinase TBK1 as a
target in KRAS-driven lung cancers. We elucidated the TBK1-regulated autocrine circuit that
promotes the survival of KRAS-driven cancers, identified a small molecule TBK1/JAK inhibitor
that inhibited the growth of KRAS-driven cancers in vivo, initiated a clinical trial involving the
combination of this TBK1/JAK inhibitor with a clinically active MEK inhibitor, and identified
mechanisms of resistance to KRAS-directed therapy.
 Based on the observation that oncogenic KRAS activates several pathways and
transcriptional programs that conspire to drive cancer initiation and progression, we anticipate
that combination strategies will be necessary to develop effective treatment regimens for KRAS-
driven lung cancers. We propose to build on our preliminary studies to identify and credential
complementary targets that will allow the development of rational combination therapies for
KRAS-driven lung cancers. We will employ genetic, biochemical and pharmacologic approaches
to eliminate c-RAF/MEK signaling, identify approaches to anticipate and target resistance
mechanisms invoked by targeting KRAS effector pathways and develop combination therapies
building on MEK and TBK1 inhibition. Specifically, we will use new technology to engender
targeted degradation of c-RAF and MEK based on thalidomide-derivatized binders, and we will
elucidate the role of, and develop therapies related to, the transcriptional regulators YAP1 and
BRD4 in resistance to KRAS pathway inhibition. These studies will be performed in close
collaboration with the other projects and cores of this Program and will inform the rational
identification and development of effective combination therapies for KRAS-driven cancers.

## Key facts

- **NIH application ID:** 10231099
- **Project number:** 5P01CA154303-10
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** William C. Hahn
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $288,552
- **Award type:** 5
- **Project period:** 2012-05-11 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10231099

## Citation

> US National Institutes of Health, RePORTER application 10231099, Project 2: Identification of combination therapy for KRAS-driven lung cancers. (5P01CA154303-10). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10231099. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*